Company: BGLC
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001477932-25-008343
Chunk: 52

Company: BioNexus Gene Lab Corp
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1
Chunk 52
---
 

 36Table of Contents

Results of Operations for the three and nine months ended September 30, 2025 compared to the three and nine months  ended September 30, 2024 (unaudited).

The following table sets forth key selected financial data for the three months and nine months ended September 30, 2025 and 2024. 

Consolidated 

  Three months ended  Nine months ended   September 30,  September 30,   2025  2024  2025  2024              REVENUE (including $25,649 and $23,456 of revenue from related parties for the three months period ended September 30, 2025 and 2024 respectively, including $57,632 and $65,380 of revenue from related parties for the nine months period ended September 30, 2025 and 2024 respectively) $2,543,823  $2,630,376  $6,941,151  $6,986,791    -   -         COST OF REVENUE (including $7,233 and $192,171 of cost of revenue from related parties for the three months period ended September 30, 2025 and 2024, respectively, including $9,404 and $293,770 of cost of revenue from related parties for the nine months period ended ended September 30, 2025 and 2024, respectively)  (2,166,138)  (2,303,840)  (5,851,951)  (6,006,504)       -         GROSS PROFIT  377,685   326,536   1,089,200   980,287        -         OTHER INCOME      -         Dividend income   4,192   38,826   21,752   59,653 Interest income  20,778   35,022   74,114   113,744 Fair value gain on investments in equity securities  -   69,765   28,256   243,083 Gain on disposal of investments in equity securities  42,376   20,800   42,376   35,098 Reversal of expected credit losses